Prot # 1263-202: A Phase 2, Randomized Study to Assess the Safety and Anti-Cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Fosc

Project: Research project

Project Details

StatusFinished
Effective start/end date10/2/127/31/15

Funding

  • Shire ViroPharma Incorporated (Prot # 1263-202)